Drugs / ABP-671
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07367971 | Jan → Jul 2026 overdue | gout | Atom Therapeutics Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT04303039 | May → Jun 2020 | gout | Atom Therapeutics Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04060173 | Sep → Dec 2019 | gout | Atom Therapeutics Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03906006 | Oct 2018 → Jun 2019 | gout | Atom Therapeutics Co., Ltd | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07323095 | Jun 2026 → Oct 2027 expected | chronic kidney disease | Atom Therapeutics Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04638543 | Nov 2020 → Oct 2021 | gout | Atom Therapeutics Co., Ltd | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06276556 | Apr → Sep 2024 | gout | Atom Therapeutics Co., Ltd | Terminated | No outcome recorded Stop: Business |
| Phase 2/3 | NCT05818085 | Aug 2023 → Jan 2025 | gout | Atom Therapeutics Co., Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABP-671 | “ABP-671 Dose 1 + Febuxostat Dose 1-tablets(PO)” NCT07323095 ↗ |
| Action | Inhibit | “ABP-671 a Novel URAT1 Inhibitor” NCT05818085 ↗ |
| Route | Oral | “single oral dose” NCT03906006 ↗ |